Your browser doesn't support javascript.
loading
Antibiotics from rare actinomycetes, beyond the genus Streptomyces.
Parra, Jonathan; Beaton, Ainsley; Seipke, Ryan F; Wilkinson, Barrie; Hutchings, Matthew I; Duncan, Katherine R.
Afiliação
  • Parra J; Instituto de Investigaciones Farmacéuticas (INIFAR), Facultad de Farmacia, Universidad de Costa Rica, San José 11501-2060, Costa Rica; Centro Nacional de Innovaciones Biotecnológicas (CENIBiot), CeNAT-CONARE, San José 1174-1200, Costa Rica.
  • Beaton A; John Innes Centre, Department of Molecular Microbiology, Norwich Research Park, Norwich NR4 7UH, UK.
  • Seipke RF; University of Leeds, Faculty of Biological Sciences, Astbury Centre for Structural Molecular Biology, Leeds LS2 9JT, UK.
  • Wilkinson B; John Innes Centre, Department of Molecular Microbiology, Norwich Research Park, Norwich NR4 7UH, UK.
  • Hutchings MI; John Innes Centre, Department of Molecular Microbiology, Norwich Research Park, Norwich NR4 7UH, UK.
  • Duncan KR; University of Strathclyde, Strathclyde Institute of Pharmacy and Biomedical Sciences, 141 Cathedral Street, Glasgow G4 0RE, UK. Electronic address: Katherine.Duncan@strath.ac.uk.
Curr Opin Microbiol ; 76: 102385, 2023 Dec.
Article em En | MEDLINE | ID: mdl-37804816
Throughout the golden age of antibiotic discovery, Streptomyces have been unsurpassed for their ability to produce bioactive metabolites. Yet, this success has been hampered by rediscovery. As we enter a new stage of biodiscovery, omics data and existing scientific repositories can enable informed choices on the biodiversity that may yield novel antibiotics. Here, we focus on the chemical potential of rare actinomycetes, defined as bacteria within the order Actinomycetales, but not belonging to the genus Streptomyces. They are named as such due to their less-frequent isolation under standard laboratory practices, yet there is increasing evidence to suggest these biologically diverse genera harbour considerable biosynthetic and chemical diversity. In this review, we focus on examples of successful isolation and genera that have been the focus of more concentrated biodiscovery efforts, we survey the representation of rare actinomycete taxa, compared with Streptomyces, across natural product data repositories in addition to its biosynthetic potential. This is followed by an overview of clinically useful drugs produced by rare actinomycetes and considerations for future biodiscovery efforts. There is much to learn about these underexplored taxa, and mounting evidence suggests that they are a fruitful avenue for the discovery of novel antimicrobials.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Streptomyces / Actinobacteria Idioma: En Revista: Curr Opin Microbiol Assunto da revista: MICROBIOLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Costa Rica País de publicação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Streptomyces / Actinobacteria Idioma: En Revista: Curr Opin Microbiol Assunto da revista: MICROBIOLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Costa Rica País de publicação: Reino Unido